Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years [0.03%]
新一代三种药物洗脱支架在生物工程随机评估中的成本效益：第3年结果
Eline H Ploumen,Martijn J Oude Wolcherink,Rosaly A Buiten et al.
Eline H Ploumen et al.
Background and objective: Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised...
Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy [0.03%]
意大利输血依赖型β地中海贫血和反复血管阻塞危象型镰状细胞病的管理相关的死亡率、临床并发症和卫生资源利用情况
Chuka Udeze,Melania Dovizio,Chiara Veronesi et al.
Chuka Udeze et al.
Objective: To examine the clinical burden and healthcare resource utilization (HCRU) among patients with transfusion-dependent β-thalassemia (TDT) and patients with sickle cell disease (SCD) with recurrent vaso-occlusive...
Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing [0.03%]
多癌症早期检测(MCED)与常规癌症筛查相结合的系统动力学模型开发及可行性测试
Mussab Fagery,Hadi A Khorshidi,Stephen Q Wong et al.
Mussab Fagery et al.
Background: Cancer screening plays a critical role in early disease detection and improving outcomes. In Australia, established screening protocols for colorectal, breast and cervical cancer have significantly contributed...
Divya Patil,Emily F Gorman,T Joseph Mattingly nd
Divya Patil
Background: Huntington's disease (HD) is associated with significant financial burden for patients and payers. The objective was to identify and quantify costs of HD by stage of disease progression. ...
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study [0.03%]
在加拿大溃疡性结肠炎和克罗恩病中将 vedolizumab 用作一线生物制剂的性价比分析：基于真实世界证据的 EVOLVE 研究结果
Aren Fischer,Stephen Mac,Erica Stivelman Freiman et al.
Aren Fischer et al.
Introduction: Vedolizumab is a gut-selective anti-lymphocyte trafficking biologic indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in Canada...
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA [0.03%]
呋喹替尼在美国治疗难治性转移性结直肠癌的 cost-effectiveness 分析
Dong-Won Kang,Patricio B Lynn,Li Wang et al.
Dong-Won Kang et al.
Background: The FRESCO-2 trial established the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. However, its cost-effectiveness in the US context is not well documented. ...
Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life [0.03%]
基因组时代新生儿筛查的现代化：健康相关生活质量的重要性
Ellen Kim DeLuca,Ann Chen Wu,Kurt D Christensen et al.
Ellen Kim DeLuca et al.
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand [0.03%]
基于泰国全国数据库2型糖尿病合并心力衰竭患者增加钠-葡萄糖共转运体2抑制剂治疗的成本效用和预算影响分析研究
Tanawan Kongmalai,Juthamas Prawjaeng,Phorntida Hadnorntun et al.
Tanawan Kongmalai et al.
Background: Heart failure (HF) in type 2 diabetes (T2D) patients poses a significant clinical and financial burden. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown cardiovascular benefits in trials, th...
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis [0.03%]
IgA肾病健康状态效用值估计：时间交易法分析
Zheng-Yi Zhou,Mark E Bensink,Nisha C Hazra et al.
Zheng-Yi Zhou et al.
Background: Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a UK societal perspective. ...
Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses [0.03%]
出版更正：2018年至2022年加拿大非肿瘤药物卫生技术评估报告的方法学批评及制造商与加拿大药物和医疗器械机构（CADTH）分析比较
Fatemeh Mirzayeh Fashami,Jean-Eric Tarride,Behnam Sadeghirad et al.
Fatemeh Mirzayeh Fashami et al.
Published Erratum
PharmacoEconomics - open. 2024 Nov;8(6):963-965. DOI:10.1007/s41669-024-00522-6 2024